molecular cytogenetics

分子细胞遗传学
  • 文章类型: Journal Article
    背景:Klinefelter综合征是一种常见的染色体(非整倍性)疾病,与男性的额外X染色体相关。无论致力于体细胞性淋球菌镶嵌性的众多研究,在临床队列中尚未系统地解决Klinefelter综合征镶嵌性(KSM)。这里,我们报道了KSM在患有神经发育障碍的大量男孩队列中的评估.此外,这些数据已被用于扩展假设,我们最近在一份关于患有神经发育障碍的女孩的特纳综合征镶嵌性的报告中提出了这一点。
    结果:在4535名男孩中的49名(1.1%)中发现了与Klinefelter综合征相关的核型。21名男孩(0.5%)为非马赛克47名XXY人。在28例(0.6%)中发现了KSM,并表现为镶嵌非整倍体(50,XXXXXY;49,XXXXY;48,XXXY;48,XXYY;47,XXY;除了47,XXY/46,XY)和源自X染色体(环染色体X和重排X染色体)的镶嵌多余标记染色体外,还检测到45,X。值得注意的是,KSM在5名男孩(0.1%)中伴有MECP2突变引起的Rett综合征样表型。
    结论:我们的研究提供了男性神经发育障碍中KSM发生的数据。因此,有人认为KSM可能是精神病和神经退行性疾病中致病级联反应的可能因素。这些观察结果使我们能够扩展我们先前报告中提出的假设,该假设是关于躯体性腺体镶嵌性(特纳综合征镶嵌性)对神经发育障碍的病因的贡献。因此,在Klinefelter综合征患者中,监测KSM(成人发病的多因素脑部疾病的可能危险因素或生物标志物)和分析衰老的神经标志物似乎很重要.两个或多个多余染色体X的病例均与KSM相关。最后,与KSM相关的Rett综合征样表型在患有神经发育障碍的男性中似乎比以前认识到的更常见。
    BACKGROUND: Klinefelter syndrome is a common chromosomal (aneuploidy) disorder associated with an extra X chromosome in males. Regardless of numerous studies dedicated to somatic gonosomal mosaicism, Klinefelter syndrome mosaicism (KSM) has not been systematically addressed in clinical cohorts. Here, we report on the evaluation of KSM in a large cohort of boys with neurodevelopmental disorders. Furthermore, these data have been used for an extension of the hypothesis, which we have recently proposed in a report on Turner\'s syndrome mosaicism in girls with neurodevelopmental disorders.
    RESULTS: Klinefelter syndrome-associated karyotypes were revealed in 49 (1.1%) of 4535 boys. Twenty one boys (0.5%) were non-mosaic 47,XXY individuals. KSM was found in 28 cases (0.6%) and manifested as mosaic aneuploidy (50,XXXXXY; 49,XXXXY; 48,XXXY; 48,XXYY; 47,XXY; and 45,X were detected in addition to 47,XXY/46,XY) and mosaic supernumerary marker chromosomes derived from chromosome X (ring chromosomes X and rearranged chromosomes X). It is noteworthy that KSM was concomitant with Rett-syndrome-like phenotypes caused by MECP2 mutations in 5 boys (0.1%).
    CONCLUSIONS: Our study provides data on the occurrence of KSM in neurodevelopmental disorders among males. Accordingly, it is proposed that KSM may be a possible element of pathogenic cascades in psychiatric and neurodegenerative diseases. These observations allowed us to extend the hypothesis proposed in our previous report on the contribution of somatic gonosomal mosaicism (Turner\'s syndrome mosaicism) to the etiology of neurodevelopmental disorders. Thus, it seems to be important to monitor KSM (a possible risk factor or a biomarker for adult-onset multifactorial brain diseases) and analysis of neuromarkers for aging in individuals with Klinefelter syndrome. Cases of two or more supernumerary chromosomes X were all associated with KSM. Finally, Rett syndrome-like phenotypes associated with KSM appear to be more common in males with neurodevelopmental disorders than previously recognized.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    目的:为了更好地了解ceritinib反应的遗传决定因素,在ASCEND-1研究中,我们对接受剂量≥300mg的ceritinib治疗的间变性淋巴瘤激酶(ALK)重排(ALK+)非小细胞肺癌(NSCLC)患者的肿瘤活检进行了探索性分析.
    方法:AXEND-1是开放标签,多中心,色瑞替尼(禁食)在ALK抑制剂(ALKi)初治或ALKi预处理的局部晚期或转移性ALK+NSCLC患者中的剂量递增和扩展研究。使用针对295个基因的FoundationMedicine小组通过下一代测序(NGS)测定活检。体细胞改变与临床结果相关(截止日期2014年4月14日)。共有285例ALK+NSCLC患者接受剂量≥300mg的色瑞替尼治疗。
    结果:NGS数据为85名患者(ALKi-预处理[n=54];ALKi-na一ve[n=31]),57是从暴露于任何ALKi之前的患者中收集的。NGS在85例患者中的14例未检测到ALK重排;这些ALKNGS阴性病例中有几例具有替代驱动因素,例如EGFR突变。71例NGS活检证实ALK重排,最常见的重排是EML4-ALK变异体1(V1)和EML4-ALKV3(分别为36.6%[26/71]和32.4%[23/71]).21名ALKi预处理的患者中有8名(6名克唑替尼预处理和2名克唑替尼预处理,随后用克唑替尼预处理)携带ALKTKD点突变,在ceritinib前1-14天进行活检;除一名G1202R点突变患者外,所有患者均从ceritinib治疗中获益.在14名ALKi初治患者中,ceritinib对几乎所有患者都有效,包括携带伴随的ERBB4和HGF扩增的患者。
    结论:这项探索性分析强调了NGS在提高我们对ceritinib反应和耐药性的认识方面的潜在作用。它还说明色瑞替尼对ALKi预处理的患者中发现的几乎所有ALK抗性突变具有活性。
    背景:ClinicalTrials.gov,NCT01283516。2011年1月26日注册,https://clinicaltrials.gov/ct2/show/NCT01283516。
    OBJECTIVE: To better understand genetic determinants of response to ceritinib, an exploratory analysis was conducted using tumor biopsies from anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small-cell lung cancer (NSCLC) patients treated with ceritinib at doses of ≥ 300 mg in the ASCEND-1 study.
    METHODS: ASCEND-1 was an open-label, multicentre, phase 1, dose-escalation and expansion study of ceritinib (fasted) in ALK inhibitor (ALKi)-naïve or ALKi-pretreated patients with locally advanced or metastatic ALK + NSCLC. Biopsies were assayed by next-generation sequencing (NGS) using a Foundation Medicine panel targeting 295 genes. Somatic alterations were correlated with clinical outcome (cut-off 14-Apr-2014). A total of 285 ALK + NSCLC patients were treated with ceritinib at doses ≥ 300 mg.
    RESULTS: NGS data were generated for 85 pts (ALKi-pretreated [n = 54]; ALKi-naïve [n = 31]), 57 were collected from patients before exposure to any ALKi. NGS did not detect ALK rearrangement in 14 of 85 patients; several of these ALK NGS negative cases harbored alternative drivers, e.g. EGFR mutation. Of the 71 biopsies with NGS confirmed ALK rearrangement, the most frequently detected rearrangements were EML4-ALK variant 1 (V1) and EML4-ALK V3 (36.6% [26/71] and 32.4% [23/71] respectively). Eight (six crizotinib-pretreated and two pretreated with crizotinib followed by alectinib) of the 21 ALKi-pretreated patients carried a point mutation of the ALK TKD, and had the biopsy collected between 1 and 14 days before ceritinib; with the exception of one patient with a G1202R point mutation, all patients derived clinical benefit from ceritinib treatment. Of the 14 ALKi-naïve patients, ceritinib was effective in almost all patients, including a patient carrying a concomitant ERBB4 and HGF amplification.
    CONCLUSIONS: This exploratory analysis highlights the potential role of NGS in improving our understanding of response and resistance to ceritinib. It also illustrates that ceritinib is active against almost all ALK resistance mutations found in ALKi-pretreated patients.
    BACKGROUND: ClinicalTrials.gov, NCT01283516. Registered January 26, 2011, https://clinicaltrials.gov/ct2/show/NCT01283516.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    BACKGROUND: In the course of evolution, chromosomes undergo evolutionary changes; thus, karyotypes may differ considerably among groups of organisms, even within closely related taxa. The genus Daucus seems to be a promising model for exploring the dynamics of karyotype evolution. It comprises some 40 wild species and the cultivated carrot, a crop of great economic significance. However, Daucus species are very diverse morphologically and genetically, and despite extensive research, the taxonomic and phylogenetic relationships between them have still not been fully resolved. Although several molecular cytogenetic studies have been conducted to investigate the chromosomal structure and karyotype evolution of carrot and other Daucus species, detailed karyomorphological research has been limited to carrot and only a few wild species. Therefore, to better understand the karyotype relationships within Daucus, we (1) explored the chromosomal distribution of carrot centromeric repeats (CentDc) in 34 accessions of Daucus and related species by means of fluorescence in situ hybridization (FISH) and (2) performed detailed karyomorphological analysis in 16 of them.
    RESULTS: We determined the genomic organization of CentDc in 26 accessions of Daucus (belonging to both Daucus I and II subclades) and one accession of closely related species. The CentDc repeats were present in the centromeric regions of all chromosomes of 20 accessions (representing 11 taxa). In the other Daucus taxa, the number of chromosome pairs with CentDc signals varied depending on the species, yet their centromeric localization was conserved. In addition, precise chromosome measurements performed in 16 accessions showed the inter- and intraspecific karyological relationships among them.
    CONCLUSIONS: The presence of the CentDc repeats in the genomes of taxa belonging to both Daucus subclades and one outgroup species indicated the ancestral status of the repeat. The results of our study provide useful information for further evolutionary, cytotaxonomic, and phylogenetic research on the genus Daucus and may contribute to a better understanding of the dynamic evolution of centromeric satellites in plants.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    BACKGROUND: Turner\'s syndrome is associated with either monosomy or a wide spectrum of structural rearrangements of chromosome X. Despite the interest in studying (somatic) chromosomal mosaicism, Turner\'s syndrome mosaicism (TSM) remains to be fully described. This is especially true for the analysis of TSM in clinical cohorts (e.g. cohorts of individuals with neurodevelopmental disorders). Here, we present the results of studying TSM in a large cohort of girls with neurodevelopmental disorders and a hypothesis highlighting the diagnostic and prognostic value.
    RESULTS: Turner\'s syndrome-associated karyotypes were revealed in 111 (2.8%) of 4021 girls. Regular Turner\'s syndrome-associated karyotypes were detected in 35 girls (0.9%). TSM was uncovered in 76 girls (1.9%). TSM manifested as mosaic aneuploidy (45,X/46,XX; 45,X/47,XXX/46,XX; 45,X/47,XXX) affected 47 girls (1.2%). Supernumerary marker chromosomes derived from chromosome X have been identified in 11 girls with TSM (0.3%). Isochromosomes iX(q) was found in 12 cases (0.3%); one case was non-mosaic. TSM associated with ring chromosomes was revealed in 5 girls (0.1%).
    CONCLUSIONS: The present cohort study provides data on the involvement of TSM in neurodevelopmental disorders among females. Thus, TSM may be an element of pathogenic cascades in brain diseases (i.e. neurodegenerative and psychiatric disorders). Our data allowed us to propose a hypothesis concerning ontogenetic variability of TSM levels. Accordingly, it appears that molecular cytogenetic monitoring of TSM, which is a likely risk factor/biomarker for adult-onset multifactorial diseases, is required.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Clinical Trial, Phase II
    目的:为了确定双antrene的当前作用,一种具有蒽环类活性的蒽,在早期研究中被证明是复发/难治性急性髓系白血病的有效治疗方法,没有明显的心脏毒性,在治疗R/RAML患者中。
    方法:本2期单中心研究(NCT03820908)招募成人R/RAML接受bisantrene(每天250mg/m2,共7天),在第1-7天通过静脉内输注2小时。疾病评估包括血常规和骨髓检查。
    结果:总而言之,招募了10名患者,中位为3种先前疗法,其中包括7名在同种异体干细胞移植后复发的患者。最常报告的≥3级治疗归因血液学不良事件为血小板减少症,而最常报告的≥3级治疗归因的非血液学AE是粘膜炎.在10个病人中,1例(10%)患者完全缓解,3例患者部分缓解,总缓解率为40%.对患者样品的下一代测序确定了与激活信号相关的一系列广泛的突变,拼接,和表观遗传修饰。
    结论:鉴于观察到的低毒性,计划进行一项将bisantrene与补充抗白血病治疗相结合的随访研究.
    OBJECTIVE: To determine the current role of bisantrene, an anthracene with anthracycline-like activity which was shown in earlier studies to be effective therapy in relapsed/refractory acute myeloid leukemia with no discernible cardiotoxicity, in the treatment of patients with R/R AML.
    METHODS: This phase 2, single-center study (NCT03820908) enrolled adult R/R AML to receive bisantrene (250 mg/m2 daily for 7 days) which was administered via an intravenous infusion over 2 hours on days 1-7. Disease assessment included routine blood work and bone marrow studies.
    RESULTS: In all, 10 patients were enrolled with a median of 3 lines of prior therapy including seven patients who had relapsed following allogeneic stem cell transplantation. The most frequently reported grade ≥3 treatment-attributed hematologic AE was thrombocytopenia, whereas the most frequently reported grade ≥3 treatment-attributed non-hematologic AE was mucositis. Of the 10 patients, one (10%) achieved a complete remission and three patients achieved a partial remission resulting in an overall response rate of 40%. Next-generation sequencing of patient samples identified a wide array of mutations associated with activated signaling, splicing, and epigenetic modification.
    CONCLUSIONS: In view of the observed low toxicity, a follow-up study combining bisantrene with complementary anti-leukemic therapy is planned.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    背景:Inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2)是一种罕见的不良预后细胞遗传学异常,存在于急性髓系白血病(AML)和其他髓系肿瘤中。
    目的:本研究的目的是评估由西班牙PETHEMA和CETLAM合作小组在1999年至2017年间进行的61例inv(3)/t(3;3)接受同质强化化疗方案治疗的新诊断AML患者队列的结局。
    方法:在这项回顾性研究中,收集了主要的临床和生物学参数。完全响应(CR)率,计算累积复发率(CIR)和总生存期(OS).对影响生存的预后因素进行分析。
    结果:61例患者接受了诱导,只有18例(29%)达到CR(中位年龄,46年)。36例(59%)患者进行异基因造血干细胞移植(alloHSCT),15患有活动性疾病。1年和4年CIR分别为52%和56%。1年和4年OS概率分别为41%和13%。通过多变量分析,单体核型(MK)与较差的OS相关(HR2.0,P=.017)。
    结论:Inv(3)/t(3;3)AML是一种预后不良实体,由于频繁和早期复发,对标准化疗和alloHSCT反应低。MK与预后较差相关。显然需要改进的治疗策略。
    BACKGROUND: Inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2) is a rare poor prognosis cytogenetic abnormality present in acute myeloid leukemia (AML) and other myeloid neoplasms.
    OBJECTIVE: The aim of this study was to evaluate the outcome of a cohort of 61 patients with newly diagnosed AML with inv(3)/t(3;3) treated with homogeneous intensive chemotherapy protocols conducted by the Spanish PETHEMA and CETLAM cooperative groups between 1999 and 2017.
    METHODS: In this retrospective study the main clinical and biologic parameters were collected. The complete response (CR) rate, the cumulative incidence of relapse (CIR) and the overall survival (OS) were calculated. An analysis of prognostic factors for survival was performed.
    RESULTS: Sixty-one patients received induction and only 18 (29%) achieved CR (median age, 46 years). Allogeneic hematopoietic stem cell transplantation (alloHSCT) was performed in 36 patients (59%), 15 with active disease. One- and 4-year CIR were 52% and 56%. One- and 4-year OS probabilities were 41% and 13%. By multivariate analysis monosomal karyotype (MK) was associated with poorer OS (HR 2.0, P = .017).
    CONCLUSIONS: Inv(3)/t(3;3) AML is a poor prognosis entity with low response to standard chemotherapy and to alloHSCT because of frequent and early relapse. MK was associated with a poorer prognosis. Improved therapeutic strategies are clearly needed.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    唾液腺的多形性腺瘤(PAs)是腮腺实性肿瘤的最常见实体。尽管如此,他们的遗传学还没有得到很好的理解。因此,当前的研究使用细胞遗传学的独特组合来表征14个PA,基于分子细胞遗传学和/或分子核型分析的方法。本研究在外周血和肿瘤组织中应用基于胰蛋白酶处理和Giemsa染色的G显带。此外,使用全染色体涂漆或着丝粒探针进行荧光原位杂交。还进行了基于阵列的比较基因组杂交。在14个案例中,有5个染色体和/或亚显微改变的特征。平衡和不平衡的易位,检测到整个染色体的丢失或获得和亚显微拷贝数改变。此外,报告了第一例PA中所谓的“跳跃易位”。扭曲相关蛋白1和非远端同源异型框5基因也参与了两个PA的拷贝数变异。总之,当前研究中使用的方法非常适合表征PA的遗传构成。
    Pleomorphic adenomas (PAs) of salivary glands are the most frequent entity of solid parotid tumors. Nonetheless, their genetics is not yet well understood. Thus, the current study characterized 14 PAs using a unique combination of cytogenetic, molecular cytogenetic and/or molecular karyotyping based approaches. The current study applied G-banding based on trypsin treatment and Giemsa-staining in peripheral blood and tumor tissue. Additionally, fluorescence in situ hybridization was performed using whole chromosome painting or centromeric probes. Array-based comparative genomic hybridization was also conducted. In 5 of 14 cases, chromosomal and/or submicroscopic alterations were characterized. Balanced and unbalanced translocations, loss or gain of whole chromosomes and submicroscopic copy number alterations were detected. Furthermore, the first case of a so-called \'jumping translocation\' in a PA was reported. The genes twist-related protein 1 and distal-less homeobox 5 were also involved in copy number variations in two PAs. In conclusion, approaches utilized in the current study are highly suited to characterize the genetic constitution of PAs.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    流产在人类中是非常常见的。本文旨在提供有关研究的已发表数据,这些数据使人们对妊娠失败有了更多的了解。澄清定义,探索从临床前到后期妊娠失败的范围,并且已经记录了用于查找损失信息的科学工具。现在理解的是,哪些工具效果最好,并讨论了相关的限制。早期研究使用细胞遗传学方法和组织培养来获得结果。实验室工具的改进,如更好的组织培养孵化器,倒置显微镜,层流罩,文化媒体的改进,所有这些都有助于为患者获得更多结果。这些研究证明了染色体核型失衡对妊娠失败的重要贡献。明确证明了产妇年龄是三体性的一个促成因素。妊娠早期流产表现出非常高的细胞遗传学异常;与以后的流产率非常低相反。在怀孕的所有时间段内组合数据将影响早期妊娠失败中染色体错误的重要性。细胞遗传学方法调查整个基因组,并被认为代表了必须验证新方法的标准。新的分子遗传学方法提供了在不需要组织培养的情况下检查样品的机会。技术可以是位点特异性或全基因组。荧光原位杂交(FISH),比较基因组杂交(CGH),基于阵列的CGH,单核苷酸多态性(SNP)检测,定量聚合酶链反应(qPCR),和定量荧光PCR(QF-PCR),都被利用了。在与经典/常规细胞遗传学的比较研究中,每种较新的方法都有优点和局限性。目前,使用常规和分子方法的组合方法将阐明几乎所有样品流产的原因。在临床设置中,这将是最佳的。
    Miscarriage is a very common occurrence in humans. This paper sets out to present published data on research that has provided increased understanding of pregnancy failure. Clarification of definitions, exploring the range of failures from preclinical to later pregnancy losses, and the scientific tools employed to find information on the losses have been documented. What is now understood, which tools work best, and the associated limitations are all discussed. Early studies used cytogenetic methods and tissue culture to obtain results. Improvements in laboratory tools such as better tissue culture incubators, inverted microscopes, laminar flow hoods, improvements in culture media, all contributed to obtaining more results for patients. These studies demonstrated the significant contribution of unbalanced chromosomal karyotypes to pregnancy failure. Maternal age as a contributing factor in trisomy was clearly demonstrated. First trimester miscarriage exhibits very high cytogenetic abnormality; in contrast to very low rates in later losses. Combining data across all time periods of pregnancy will affect the significance of chromosomal error in the early pregnancy failures. Cytogenetic methods investigate whole genomes, and are considered to represent the standard against which new methods must be validated. New molecular genetic methods provide the opportunity to examine samples without the necessity of tissue culture. Techniques may be site-specific or whole genome. Fluorescent in situ hybridisation (FISH), comparative genomic hybridisation (CGH), array-based CGH, single nucleotide polymorphism (SNP) detection, quantitative polymerase chain reaction (qPCR), and quantitative fluorescent PCR (QF-PCR), have all been utilised. In comparison studies with classical/conventional cytogenetics, each newer method offers advantages and limitations. At the present time, a combined approach using conventional and molecular methods will elucidate the cause of miscarriage for almost all samples. In a clinical setting this would be optimum.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    目的:这项研究旨在确定新诊断的急性淋巴细胞白血病(ALL)年龄<19岁的儿童染色体畸变的频率,在儿科和放射科就诊/入院,政府医学院,查谟.此外,我们旨在研究细胞遗传学分子异常与即时临床结局(诱导缓解)之间的相关性.
    方法:这是一项前瞻性研究,为期2年(2011年5月至2013年5月),在印度一家三级保健医院进行。40名儿科(1-19岁)患者(18名男性,22名女性;M:F=0.8:1)对新诊断的ALL进行了分子细胞遗传学分析。从患者的父母获得书面同意。进行骨髓穿刺以诊断ALL。失去随访和未能同意的儿童被排除在调查之外。从患者获得宿主因子和临床参数。
    结果:对40例确诊的ALL患者的骨髓抽取物样本进行常规细胞遗传学分析,采用逆转录-聚合酶链反应(RT-PCR)技术进行分子分析。在18/40(45%)的病例中获得了分布良好的中期板用于分析。RT-PCR显示20/40(50%)患者的基因异常。分子细胞遗传学分析的结果与患者的临床和血液学参数相关,以进行风险分层和立即结果(诱导缓解)。40例中有18例(45%)未发现异常。在其余22个案件中,8有TEL-AML1(20%),6人患有BCR-ABL(15%),4有MLL-AF4(10%),2具有E2A-PBX1(5%)融合基因,和2有超二倍体。最后,在这项研究中,较高比例的病例表现出不良易位,如t(9;22),t(4;11),和t(1;19)与文献报道的相比。
    结论:RT-PCR检测可用于检测具有预后意义的癌基因融合转录本。在我们对40名患者的研究中,我们发现模式和频率与西方文献报道的不同。我们的研究表明,在儿童ALL中,超二倍体的频率较低(5%),而BCR-ABL基因融合的频率较高(20%)。最重要的是,与以前关于儿童ALL的研究相反,我们的研究表明女性占主导地位,男女比例为0.8:1。除了BCR-ABL融合基因,没有其他人与不良预后相关。已经确定的是,在诊断时对遗传实体的表征对于ALL的理解和最佳治疗是至关重要的。因为我们人口的畸变与西方人口的畸变有很大不同,我们可能需要调整我们的协议。
    OBJECTIVE: This study was conducted to determine the frequency of chromosomal aberrations in children aged <19 years with newly diagnosed acute lymphoblastic leukemia (ALL), attending/admitted in the Department of Pediatrics and Radiotherapy, Government Medical College, Jammu. Furthermore, we aimed to study the correlation between the cytogenetic molecular abnormalities and the immediate clinical outcome (induction of remission).
    METHODS: This was a prospective study conducted over a period of 2 years (May 2011 to May 2013) in a tertiary care hospital in India. Forty pediatric (1-19 years) patients (18 males, 22 females; M: F = 0.8 : 1) with newly diagnosed ALL were studied for molecular cytogenetic analysis. Written consent was obtained from the parents of the patients. Bone marrow aspiration was done for making the diagnosis of ALL. Children lost to follow-up and who failed to give consent were excluded from the survey. Host factors and clinical parameters were obtained from patients.
    RESULTS: Bone marrow aspirate samples of 40 diagnosed cases of ALL were subjected to routine cytogenetic analysis, and reverse transcription-polymerase chain reaction (RT-PCR) technique was used for molecular analysis. Well-spread metaphase plates were obtained in 18/40 (45%) cases for analysis. RT-PCR revealed abnormal genes in 20/40 (50%) patients. The results of molecular cytogenetic analysis were correlated with patients\' clinical and hematological parameters for risk stratification and immediate outcome (induction of remission). Eighteen out of 40 (45%) cases revealed no abnormality. Among the remaining 22 cases, 8 had TEL-AML1 (20%), 6 had BCR-ABL (15%), 4 had MLL-AF4 (10%), 2 had E2A-PBX1 (5%) fusion genes, and 2 had hyperdiploidy. To conclude, a higher proportion of cases in this study showed adverse translocations such as t (9;22), t (4;11), and t (1;19) compared to that reported in literature.
    CONCLUSIONS: RT-PCR assay was useful in detecting the prognostically significant oncogene fusion transcripts. In our study of 40 patients, we found that the pattern and frequency differ from those reported in Western literature. Our study reveals a lower frequency of hyperdiploidy (5%) and a higher frequency of BCR-ABL gene fusion (20%) in childhood ALL. Above all, in contrast to previous studies on childhood ALL, our study showed female predominance, with the male-to-female ratio being 0.8 : 1. Apart from the BCR-ABL fusion gene, none other was associated with poor prognosis. It is already well established that the characterization of the genetic entities at diagnosis is crucial for the understanding and the optimal treatment of ALL. Because the aberrations in our population differ significantly from those reported in Western populations, we may be required to tailor our protocols.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

公众号